Inhibition of Histone Deacetylase Activity Increases Cisplatin Efficacy to Eliminate Metastatic Cells in Pediatric Liver Cancers
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jun 2024 · 1 min read
In brief
In brief
This study demonstrates that combining HDAC inhibitors with cisplatin enhances elimination of metastasis-initiating cells in pediatric liver cancers. Researchers identified elevated HDAC1 expression in cancer-associated fibroblasts and neuron-like cells within the metastatic microenvironment, showing that vorinostat augments cisplatin's anti-tumor effects against these resistant cell populations.
Written by the GCMD Library team from the article.
Statements in this article
Hepatoblastoma and hepatocellular carcinoma often spread to the lungs.
Cisplatin may not eliminate metastasis-initiating cells in pediatric liver cancers.
The metastatic microenvironments of hepatoblastoma contain Cancer Associated Fibroblasts (CAFs) and neuron-like cells, which initiate cancer spread from liver to lungs.
CAFs and neuron-like cells in hepatoblastoma metastatic microenvironments express high levels of HDAC1.
Both HBL and HCC tissue specimens have increased HDAC1-Sp5 pathway activation.
HDAC inhibition with vorinostat (SAHA) increases cisplatin efficacy to eliminate CAFs in hepatoblastoma and hepatocellular carcinoma cell lines.